These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 25303294)

  • 1. CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure.
    Mukonzo JK; Nanzigu S; Waako P; Ogwal-Okeng J; Gustafson LL; Aklillu E
    Pharmacogenomics; 2014 Aug; 15(11):1423-35. PubMed ID: 25303294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study.
    Habtewold A; Makonnen E; Amogne W; Yimer G; Aderaye G; Bertilsson L; Burhenne J; Aklillu E
    Pharmacogenomics; 2015; 16(10):1047-64. PubMed ID: 25831219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.
    Mukonzo JK; Okwera A; Nakasujja N; Luzze H; Sebuwufu D; Ogwal-Okeng J; Waako P; Gustafsson LL; Aklillu E
    BMC Infect Dis; 2013 Jun; 13():261. PubMed ID: 23734829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis.
    Ngaimisi E; Mugusi S; Minzi O; Sasi P; Riedel KD; Suda A; Ueda N; Janabi M; Mugusi F; Haefeli WE; Bertilsson L; Burhenne J; Aklillu E
    Clin Pharmacol Ther; 2011 Sep; 90(3):406-13. PubMed ID: 21814190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment.
    Ngaimisi E; Minzi O; Mugusi S; Sasi P; Riedel KD; Suda A; Ueda N; Bakari M; Janabi M; Mugusi F; Bertilsson L; Burhenne J; Aklillu E; Diczfalusy U
    J Antimicrob Chemother; 2014 Dec; 69(12):3311-9. PubMed ID: 25096076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin.
    Mugusi S; Ngaimisi E; Janabi M; Mugusi F; Minzi O; Aris E; Bakari M; Bertilsson L; Burhenne J; Sandstrom E; Aklillu E
    Eur J Clin Pharmacol; 2018 Nov; 74(11):1405-1415. PubMed ID: 30003275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy.
    Lee KY; Lin SW; Sun HY; Kuo CH; Tsai MS; Wu BR; Tang SY; Liu WC; Chang SY; Hung CC
    PLoS One; 2014; 9(2):e88497. PubMed ID: 24551111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype.
    Kitabi EN; Minzi OMS; Mugusi S; Sasi P; Janabi M; Mugusi F; Bertilsson L; Burhenne J; Aklillu E
    Sci Rep; 2018 Nov; 8(1):16316. PubMed ID: 30397233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population.
    Mukonzo JK; Bisaso RK; Ogwal-Okeng J; Gustafsson LL; Owen JS; Aklillu E
    Pharmacogenomics; 2016 Apr; 17(6):603-13. PubMed ID: 27045425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.
    Habtewold A; Aklillu E; Makonnen E; Amogne W; Yimer G; Aderaye G; Bertilsson L; Owen JS; Burhenne J
    J Clin Pharmacol; 2016 Dec; 56(12):1538-1549. PubMed ID: 27125860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe.
    Dhoro M; Zvada S; Ngara B; Nhachi C; Kadzirange G; Chonzi P; Masimirembwa C
    BMC Pharmacol Toxicol; 2015 Mar; 16():4. PubMed ID: 25889207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of genetic polymorphisms in cytochrome P450 and effects of tuberculosis co-treatment on the predictive value of CYP2B6 SNPs and on efavirenz plasma levels in adult HIV patients.
    Bienvenu E; Swart M; Dandara C; Ashton M
    Antiviral Res; 2014 Feb; 102():44-53. PubMed ID: 24316028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients.
    Habtewold A; Amogne W; Makonnen E; Yimer G; Riedel KD; Ueda N; Worku A; Haefeli WE; Lindquist L; Aderaye G; Burhenne J; Aklillu E
    J Antimicrob Chemother; 2011 Oct; 66(10):2350-61. PubMed ID: 21846671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation.
    Kwara A; Lartey M; Sagoe KW; Xexemeku F; Kenu E; Oliver-Commey J; Boima V; Sagoe A; Boamah I; Greenblatt DJ; Court MH
    J Clin Pharmacol; 2008 Sep; 48(9):1032-40. PubMed ID: 18728241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of rifampicin,
    Zhang L; Meng X; Dong P; Qi T; Liu L; Wang B
    Int J STD AIDS; 2023 Jan; 34(1):37-47. PubMed ID: 36356965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
    Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
    Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
    Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
    Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients.
    Maganda BA; Minzi OM; Ngaimisi E; Kamuhabwa AA; Aklillu E
    Pharmacogenomics J; 2016 Feb; 16(1):88-95. PubMed ID: 25963334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2B6 18492T->C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1.
    Manosuthi W; Sukasem C; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S
    Antimicrob Agents Chemother; 2014; 58(4):2268-73. PubMed ID: 24492364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment.
    von Braun A; Castelnuovo B; Ledergerber B; Cusato J; Buzibye A; Kambugu A; Fehr J; Calcagno A; Lamorde M; Sekaggya-Wiltshire C
    J Antimicrob Chemother; 2019 Jan; 74(1):135-138. PubMed ID: 30239753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.